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ABSTRACT
Factor XIII (FXIII) deficiency is an extremely rare bleeding disorder with an
approximately 12-times higher than the rest of the world. The
International Society for Thrombosis and Hemostasis (ISTH) suggested a
standard algorithm for precise diagnosis and classification of FXIII
deficiency (FXIIID). However, due to lack of investment in proper
equipment and procedures in Iran, almost no part of this algorithm can
be used to diagnose Iranian patients. Thus, this study proposes
a guideline for accurate molecular and laboratory diagnosis of FXIIID
based on the available tools. Because this study suggests a simple and
reliable algorithm for early diagnosis, it can therefore, reduce the rates of
morbidity and mortality of FXIIID patients with this condition.
Keywords: factor XIII deficiency, laboratory diagnosis, Iran, ISTH, devel-
oping countries, rare bleeding disorders
Factor XIII (FXIII) deficiency is a rare bleeding disorder (RBD)
with an estimated global incidence of 1 per 2 million. With a
high rate of consanguinity, Iran has the highest global incidence
of FXIII deficiency (FXIIID) with 483 patients in 2016.1 This RBD
is associated with a high rate of life threatening bleeding
episodes, including recurrent pregnancy loss (RPL), umbilical
cord bleeding, and intracranial hemorrhage. Central nervous
system (CNS) bleeding is a common bleeding diathesis,
observed in 32% of Iranian patients with severe congenital
FXIIID, which leads to a high rate of morbidity and mortality.2,3
Life-threatening bleeding episodes can be reduced significantly
with timely diagnosis of FXIIID and appropriate prophylaxis
utilizing blood-derived components such as fresh frozen
plasma (FFP) and FXIII concentrate, or recombinant FXIII
(rFXIII).3 Clinical presentations offer suitable clues for diagnosis
of this disorder.4
Diagnosis of Factor XIII
Deficiency
Because FXIII (as a coagulation factor) is not involved in the
formation of an early unstable clot, all routine coagulation
tests, including bleeding time (BT), prothrombin time (PT),
and activated partial thromboplastin time (APTT), show
normal results in FXIIID, which complicates the diagnosis.
Clot formation, which forms the basis of the aforementioned
tests, is normal in FXIIID.5,6 At the end of the coagulation
cascade, when an early clot is formed, FXIII covalently cross-
links the unstable fibrin and forms a firm, stable clot.7
Therefore, stability assessment of the formed clot can be
used as a screening test for FXIIID.8 The clot-solubility test
has been used since 1960 to detect FXIIID.9 In brief, an
anticoagulated blood specimen is centrifuged, and the
resulting plasma is clotted by calcium chloride (CaCl2). Then,
the formed clot is suspended in 5 M urea or
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monochloroacetic (MCA) acid solutions and incubated at
37C or at room temperature. Then clot is evaluated at
regular intervals for dissolution.5,9,10
The clot solubility test is not sensitive and is no longer
recommended for screening of FXIIID; quantitative assays
should be used to determine the exact plasma level of the
FXIII.6 However, the clot solubility assay is still used in a
considerable number of laboratories because of its simplicity
and due to the lack of availability of the quantitative
screening assay in most routine laboratories.5,6,9 The
International Society for Thrombosis and Hemostasis (ISTH)
proposed the following algorithm for proper diagnosis and
classification of FXIIID (Figure 1).11
After measurement of FXIII activity and antigen assay to
determine the presence of FXIII inhibitor, a mixing study
usually is helpful. In cases with abnormal clot solubility test
results, it may be necessary to determine factor deficiency
or presence of an inhibitor in a mixing study; the clot
solubility assay is performed on a mixture of patient
plasma and a similar volume of normal plasma (1:1
proportion). If the result of the assay is corrected, it may be
suggestive of a congenital deficiency; if not, an inhibitor to
FXIII may be present. Clot-based inhibitor assays are only
able to detect neutralizing antibodies. If non-neutralizing
antibodies are present, a binding assay is recommended.
In this method, immunoglobulin G (IgG) antibodies in the
patient plasma are bound to purified FXIII-A2B2, FXIII-A2,
and FXIII-B coated to a microtiter plate via enzyme-linked
immunosorbent assay (ELISA) or bound to sodium dodecyl
sulfate (SDS) via the polyacrylamide gel electrophoresis
(PAGE) method. In the PAGE method, the plasma
specimen is mixed with SDS that is used as a negative
charge for the bound polypeptide proportionate to its
mass. The specimen then undergoes electrophoresis on a
polyacrylamide gel; proteins will be separated based on
their size.11,12
This algorithm presents a reliable diagnostic approach.
However, in almost all clinical laboratories in Iran and a
considerable number of laboratories in the developed world
(approximately 20%), the primary available screening test is
the clot solubility test, which is not of value in this
algorithm.5,6 Until the required equipment and facilities are
available throughout Iran, using a regional diagnostic
algorithm seems to be necessary.6
Diagnosis of Factor XIII
Deficiency in Iran
Proper diagnosis and classification of FXIIID using a set of
laboratory assessments according to international standards
is largely unavailable in Iran due to high costs, coupled with a
low number of patients (N ¼ 483).6 Thus, most of these
standard assessments are not available. The diagnosis of
FXIIID is based on clinical presentations; family history; and
laboratory assessment via clot solubility test, FXIII activity
assay and, most recently, inhibitor assay.13-16 Standardization
and troubleshooting of available tests are crucial.6,8,11 In Iran,
a patient suspected of having FXIIID is assessed by routine
coagulation tests, including PT, PTT, BT, and platelet count.
When a normal result is obtained in these tests, the clot
solubility test is performed next.6 Because this test has low
sensitivity and specificity and is affected by a number of
factors, such as fibrinogen level, clotting agents, and
solubilizing factors, it cannot be used as a confirmatory test.9
Molecular diagnosis of FXIIID is not widely used in Iranian
patients; however, a number of hemophilia and research
centers use molecular tests to confirm diagnosis of severe
congenital FXIIID, for carrier detection and prenatal diagnosis
(PND).1,4,13
Laboratory Investigation of
Patients With Factor XIII
Deficiency
Clot Solubility Test
The only screening assay available for FXIIID in Iran is
the clot solubility test; this test is affected by several
interfering factors and has low sensitivity and
specificity.6,15 To date, a standard procedure has not
been developed; however, several methods and changes
have improved it. At baseline, blood is collected with a
ratio of 1:9 in 3.2% sodium citrate anticoagulant. The
whole blood specimen then is centrifuged to obtain
platelet-poor plasma (PPP). After PPP preparation, a
clotting agent is added to PPP, and the integrity of the
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Table 1. Detected Mutations in Iranian Patients With Factor XIII Deficiency and Suggested Primers
Mutation Exon Patients, No. (%) Detection Technique Primer Annealing Digestion Enzyme Reference
Trp187Arg 4 346 (97.1) PCR-RFLP F: 50-TTGCAGACTTGCCTGATTTG-30 58 Eco130I 22
R: 50-CAAGCGATCCTCCCATCTTG-30
Arg77His 3 5 (1.4) PCR-RFLP F: 50-TGCTACCTGCCTTCTTCAGG-30 56 Aci I 22
R: 50-CCTGCCACTGTTGACATATG-30
Arg260Cys
& Arg260His
6 2 (0.6) PCR sequencing F: 50-GCTTGCAGAGTGAACACTAGTTT-30 54 NA 1
R: 50-TGACAGGTGTTAACAGATTTTAGG-30
c.689delA 5 1 (0.3) PCR sequencing F: 50-AAGTGTTTGGAAACAGTCTGG-30 54 NA 1
R: 50-ATGAAGTAAAAATGTCCTTGAC-30
Arg382Ser 9 1 (0.3) PCR-RFLP F: 50-CACTTCTTGATCTCTTGGAGCA-30 56 Hae III 1
R: 50-AGATCAGCAATGAAGCAAGTTC-30
c.1981delC 14 1 (0.3) PCR sequencing F: 50-AGAGCAGAACGAGGTTTT-30 52 NA 1
R: 50-GCTTCCCACAGCTCTGCAC-30
PCR-RFLP, polymerase chain reaction–restriction fragment length polymorphism; PCR, polymerase chain reaction.
1. A quantitative FXIII activity assay as 
2. Measurement of FXIII antigen 
    (FXII-A2B2, FXIII-A, FXIII-B)
3. Detection of autoantibody against FXIII
    a) Mixing study for neutralizing antibodies
    b) Binding assay for non-neutralizing antibodies
4. Sodium dodecylsulfate–polyacrylamide (SDS-PAGE)
5. Molecular diagnosis of FXIIID
If FXIII activity is decreased,
follow step 2
In patients suspected 
of harboring acquired FXIIID
Figure 1
Suggested algorithm by International Society for Thrombosis and Hemostasis (ISTH) for proper diagnosis and classification of factor XIII
deficiency. FXIII indicates Factor XIII; FXIIID, FXIII disorder.
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formed clot is assessed at regular intervals.9,12 The
most common solvents include urea or MCA solution
and acetic acid. Different clotting agents, including
thrombin, calcium, and calcium in combination with
thrombin, have been introduced. Several studies9,12 have
determined the specificity and sensitivity of various
combinations of clotting and solubilizing factors. In Iran,
the most common method of clot solubility test is a
combination of CaCl2 as a clotting agent and MCA as a
solvent reagent. This method is less sensitive than others
and shows abnormal results only in severe FXIIID
cases.12
It has been suggested that the calcium/urea method is
sensitive to 1 to 5 U/mL of FXIII, whereas thrombin/acetic
acid is sensitive to at least 10U/mL. Calcium/acetic acid and
thrombin/urea methods are reported to provide intermediate-
level sensitivity. Although the acetic acid–based assay is
more sensitive and rapid than the urea solubility test, it is
less specific.9,12
Factor XIII Activity Assay
FXIII activity assay is a specific test for precise detection and
confirmation of diagnosis. Until recently, this assay was
rarely used for diagnosis of FXIIID in Iran.6 This test currently
is restricted to referral coagulation laboratories. Several
methods have been introduced for FXIII functional assays,
including photometric, putrescine incorporation, and
fluorometric.5,6,12
In the commonly used photometric assay, activated FXIII (FXIIIa)
crosslinks the amine substrate in the glutamine residue of the
a2-plasmin inhibitor. During this reaction, ammonia is released
and used for glutamine formation, and nicotinamide adenine
dinucleotide phosphate hydrogen (NADPH) is transformed to
nicotinamide adenine dinucleotide phosphate hydrogen
(NADP). The decrease in NADPH level causes absorbance
reduction at 340nm, which indicates FXIIIa activity.10,11,16
Among activity assays, the putrescine incorporation assay is a
highly sensitive but time-consuming method.10,11
Image 1
Iranian provinces in which the greatest number of cases of Factor XIII deficiency are found.
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Molecular Diagnosis of Factor XIII Deficiency
in Iran
Molecular diagnosis of FXIIID is rarely performed in Iran.
Most diagnoses of the condition have been performed in
southeast Iran, which has the highest incidence of FXIIID
worldwide.1,6 Several studies1,4,17 indicate that Trp187Arg is
the only FXIIID-causing mutation in this area, due to the
founder effect (the founder effect is the loss of genetic
variation in a new population that is established by small
number of people from a larger population). Another study on
Iranian patients found His77Arg to be another common
disease-causing mutation. Several other mutations were
found but not observed recurrently. Regarding these studies,
in a patient suspected of having FXIIID, Trp187Arg should be
the first selected mutation for diagnosis or confirmation of
the condition. The Arg77His mutation on exon 3 should be
selected as the second disease-causing mutation.1,18
Sequencing of exon number 6 of the FXIII-A gene should
follow because the second most common mutations
Arg260Cys and Arg260His have been observed among
Iranian patients1,18 (Table 1).
c.68
F
Ex
Ex
FX
FX
9delA 
actor XIII deficiency
Trp187Arg
Arg77His
on 6 sequencing
on 5 sequencing
II-A sequencing
II-B sequencing
Arg260C
Arg382Se
ys A
r Exon 6 
c.19
rg260His
sequencing
81delC 
Figure 2
Suggested algorithm for molecular diagnosis of factor XIII deficiency in Iran.
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Because FXIII-A has 15 exons, sequencing of other exons
that have established mutations in Iranian patients, including
exons number 5, 9, and 14, should be considered before full
sequencing of FXIII-A. If full sequencing of FXIII-A detects
no mutation, FXIII-B sequencing should be performed.
An Algorithm for Diagnosis of
Factor XIII Deficiency in Iran
Regarding available data about Iranian patients with FXIIID, a
specific diagnostic algorithm can be proposed for reliable,
early, one-time diagnosis. The majority of Iranian patients with
FXIIID displays a wide spectrum of clinical presentations.1,4,18-
20 Their clinical manifestations can provide clues for timely
diagnosis of FXIIID. Umbilical cord bleeding is the most
common presentation strongly suggestive of FXIIID in Iran, as
it is elsewhere.1,21 Moreover, recurrent miscarriage,
intracranial hemorrhage, and soft tissue hematoma have been
reported, along with delayed and prolonged wound bleeding.1
After precise physical examination and assessment of clinical
presentations, precise family history is the second-most-
helpful diagnostic criterion.15 A study of 190 Iranian patients
indicated that 78% of patients had parents who were close
relatives genetically and 12% had parents who were distant
relatives genetically, whereas only 10% had parents who were
not genetically related.15 Therefore, a precise, detailed family
history is important.
Suspected Bleeding episodes to 
factor XIII deficiency
Family history
NegativePositive
Origin of patients
Sistan and Baluchestan, Kerman, Yazd, 
Khorasan Razavi, Golestan provinces
Positive Negative
Trp187Arg
Routine coagulation tests
(PT, PTT, BT and platelet 
count)
Normal Abnormal
Clot solubility test
Abnormal Normal
Facto XIII assay
Positive
Factor XIII 
assay
Negative
Investigation bleeding disorders other 
than factor XIII deficiency
(Other coagulation factor deficiency, 
platelet function and vascular and 
acquired bleeding disorders)
Molecular algorithm 
Figure 3
Suggested algorithm of diagnosis of factor XIII deficiency in Iran.
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In a patient with a positive family history for FXIIID, the
third appropriate step toward proper diagnosis is to
address the question of ethnic origin. Of the 473
reported patients with FXIIID in Iran, 352 were residents
of the Sistan and Baluchestan province in southeastern
Iran and 62 patients were residents of the Kerman,
Khorasan Razavi, Yazd, and Golestan provinces, which
have a relatively high rate of relocation from Sistan and
Baluchistan1 (Image 1). Two studies1,22 determined that
the FXIIID-causing mutation in Sistan and Baluchestan
Province is Trp187Arg, which emphasizes a founder
effect. In a patient from Sistan and Baluchestan Province
with a positive family history for FXIIID, a simple but
reliable polymerase chain reaction–restriction fragment
length polymorphism (PCR-RFLP) test can lead to early
confirmation of the deficiency.
Because approximately all Iranian provinces with a high
number of patients with FXIIID live in the vicinity of Sistan and
Baluchestan Province or have a high rate of migration from
this province, Trp187Arg should be selected as the first
molecular test for FXIIID diagnosis in every Iranian patient. In
a patient with a negative family history for FXIIID and without
origins from Sistan, Baluchestan, Kerman, Khorasan Razavi,
Yazd, or Golestan provinces, all routine coagulation tests
should be performed at baseline. Normal results of these
tests would rule out most other bleeding disorders (Figure 2).
A normal result in routine coagulation tests can be followed by
the clot solubility test. In this step, one can obtain a normal or
abnormal result in the solubility assay. Due to the low
specificity of clot solubility, an abnormal result of this test
should be followed by more reliable tests, such as the FXIII
activity assay. Finally, with a proper molecular approach,
the molecular basis of this disease can be distinguished
(Figure 3). LM
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